Avoralstat
- Generic Name
- Avoralstat
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27N5O5
- CAS Number
- 918407-35-9
- Unique Ingredient Identifier
- UX17773O15
- Background
Avoralstat has been used in trials studying the prevention of HAE and Hereditary Angioedema.
Clearside's CLS-AX Phase 2b Trial Data Shows Promise in Treatment-Naïve AMD Patients
• New subgroup analyses from Clearside Biomedical's ODYSSEY Phase 2b trial provide strategic insights for upcoming Phase 3 program in neovascular age-related macular degeneration.
• Data presented at the Angiogenesis 2025 meeting supports focusing on treatment-naïve patients and implementing specific visual acuity criteria for future trials.
• The 36-week ODYSSEY trial employed a robust design, being randomized, double-masked, and active-controlled across multiple centers.
Krystal Biotech and CRISPR Therapeutics Announce Key Updates in Gene Therapy Programs
• Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.
• Krystal Biotech's KB407 for cystic fibrosis received full sanctioning for its Phase 1 CORAL-1 study, with interim molecular data expected mid-2025.
• CRISPR Therapeutics reported positive momentum in the CASGEVY launch, with over 50 activated treatment centers and patients initiating cell collection globally.
• CRISPR Therapeutics expects key clinical data updates in 2025 for CTX112 in oncology and autoimmune diseases, and for CTX310 and CTX320 in cardiovascular programs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath